title: Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities.
abstract: In the present study, the expression of cyclin D1, as detected by immunohistochemistry, was compared with other prognostic variables and its prognostic impact was evaluated in a group of 172 patients with squamous cell carcinoma (SCC) of the esophagus who underwent potentially curative resection therapy and in a second group of 38 patients with SCC of the esophagus who were treated by combined modality therapy (radiochemotherapy +/- surgery). Expression of cyclin D1 in surgically treated carcinomas correlated negatively with tumor differentiation (p = 0.026) but positively with mitotic activity (p = 0.0199) and nodal status (p = 0.040). There were no significant correlations with pT category. Patients with cyclin D1-positive carcinomas showed significantly worse overall survival than patients with cyclin D1-negative carcinomas, both in univariate (p = 0.0016) and in multivariate survival analyses (p = 0.0038). Expression of cyclin D1 in carcinomas with multimodal treatment was correlated with poor response to chemotherapy (p = 0.026) but not with overall survival. We thus consider expression of cyclin D1 to be an important parameter, predicting an unfavorable overall survival of surgically treated esophageal cancer patients.
authors.affiliation: Department of Pathology, Heinrich Heine Universität, Düsseldorf, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Sarbia
authors.forename: M
authors.initials: M
authors.lastname: Stahl
authors.forename: U
authors.initials: U
authors.lastname: Fink
authors.forename: H
authors.initials: H
authors.lastname: Heep
authors.forename: P
authors.initials: P
authors.lastname: Dutkowski
authors.forename: R
authors.initials: R
authors.lastname: Willers
authors.forename: S
authors.initials: S
authors.lastname: Seeber
authors.forename: H E
authors.initials: HE
authors.lastname: Gabbert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000601:surgery / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D019938:Cyclin D1 / Q000096:biosynthesis*; D015251:Epirubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000601:surgery / Q000628:therapy; D004947:Esophagus / Q000378:metabolism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D011379:Prognosis; D015996:Survival Rate